Kyowa Kirin Co., Ltd. is a global biopharmaceutical company headquartered in Tokyo, Japan, specializing in the discovery, development, and commercialization of innovative therapies for oncology, nephrology, and immunology. Founded in 1949 as Green Cross, the company underwent a major reorganization in 2005 to form Kyowa Hakko Kirin, which later became Kyowa Kirin in 2019. Drawing on its proprietary antibody technologies and peptide drug platforms, the company focuses on delivering targeted treatments for patients with serious and rare diseases.
The company’s core product portfolio includes Poteligeo (mogamulizumab), a monoclonal antibody indicated for certain types of lymphoma, and Crysvita (burosumab), an antibody therapy for X-linked hypophosphatemia. In addition, Kyowa Kirin markets Nesp (darbepoetin alfa) for anemia associated with chronic kidney disease and oncology indications, alongside a range of supportive care and specialty pharmaceuticals. The organization maintains a robust pipeline with candidates in late-stage development for conditions such as multiple myeloma, central nervous system disorders, and autoimmune diseases.
Operating across Japan, North America, Europe, and Asia-Pacific regions, Kyowa Kirin leverages strategic partnerships and regional subsidiaries to accelerate market access and localize clinical development. The company’s manufacturing network includes state-of-the-art facilities in Japan and Ireland, ensuring global supply continuity and compliance with international regulatory standards. Collaborative research alliances with academic institutions and biotechnology firms further strengthen its R&D capabilities.
Under the leadership of President and Chief Executive Officer Hisashi Gotoh, Kyowa Kirin emphasizes sustainable growth through innovation, patient-centricity, and environmental stewardship. The executive team champions initiatives in digital health, data science, and green chemistry to enhance operational efficiency and reduce the company’s environmental footprint. As a member of the global pharmaceutical community, Kyowa Kirin continues to pursue scientific excellence and expand its contributions to improving patient outcomes worldwide.
AI Generated. May Contain Errors.
Free KYKOF Stock Alerts